Hemoglobin, albumin, lymphocyte, and platelet score as a predictor of prognosis in metastatic gastric cancer

Table 2 Distribution of patients according to hemoglobin, albumin, lymphocyte, and platelet score in subgroups

Features	HALP low, n (%)	HALP high, n (%)	P value
Gender			0.816
Female	23 (25.8)	14 (24.2)
Male	66 (74.2)	44 (75.9)
ECOG PS			0.02
0	16 (18)	16 (27.6)
1	47 (52.8)	36 (62.1)
2	26 (29.2)	6 (10.3)
Comorbidity			0.008
No	37 (41.6)	37 (63.8)
Yes	52 (58.4)	21 (36.2)
Smoking			0.679
No	43 (48.3)	26 (44.8)
Yes	46 (51.7)	32 (55.2)
Surgery			0.804
No	56 (62.9)	34 (58.6)
Yes	33 (37.1)	24 (41.4)
Type of surgery			0.783
No	55 (61.8)	34 (58.6)
Total gastrectomy	23 (25.8)	18 (31)
Subtotal gastrectomy	10 (11.2)	6 (10.3)
Patology			0.18
Adenocarcinom	79 (88.8)	49 (84.5)
Signet ring cell carcinom	8 (9)	7 (12.1)
Musinoz adenocarcinom	2 (2.2)	0 (0)
Mix carcinom	0 (0)	2 (3.4)
Diferantiation			0.045
Well	1 (1.1)	4 (6.9)
Moderate	42 (47.2)	32 (55.2)
Poorly	38 (42.7)	14 (24.1)
Signet ring cell carcinoma	8 (9)	8 (13.8)
Tumor location			0.142
Fundus, cardia	25 (28.1)	23 (39.7)
Corpus	33 (37.1)	23 (39.7)
Antrum, pylor	31 (34.8)	12 (20.7)
De novo metastasis			0.894
No	27 (30.3)	17 (29.3)
Yes	62 (69.7)	41 (70.7)

ECOG PS: Eastern Cooperative Oncology Group Performance status; HALP: Hemoglobin, albumin, lymphocyte and platelet.